Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Modality
Small molecule
Development Phase
Phase 2/3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
46High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06805812CT.gov Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study | — | Recruiting | — | — | — |
NCT06525675CT.gov Study to Evaluate the Extended Overall Survival (OS) Data From PARSIFAL Study (The PARSIFAL-LONG Study) | — | Completed | — | — | — |
NCT02692755CT.gov Palbociclib / Letrozole or Fulvestrant in African American Women With HR+ HER2- Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Tumor Luminal A Or B
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Palbociclib (this asset) | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | P2/3 | B · 58 |
| Letrozole | BeOne Medicines | P4 | BB |
| Fulvestrant | BeiGene | P2/3 | B |
| Elacestrant | GBG Forschungs GmbH | P2 | B |
| Cyclophosphamide | Puma Biotechnology, Inc. | P3 | B |
| Carboplatin | Fudan University | P3 | B |
| Epirubicin | Fudan University | P3 | B |
| Durvalumab | University Health Network, Toronto | P2 | B |
| Docetaxel | Fudan University | P3 | B |
+16 more in the Breast Tumor Luminal A Or B cohort
Other indications for Palbociclib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 75 |
| Hormone Receptor-Positive Breast Cancer | — | P3 | BBB · 73 |
| Breast Cancer | — | P4 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Palbociclib in Breast Tumor Luminal A Or B. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/palbociclib-breast-tumor-luminal-a-or-b
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →